Omenn syndrome (OS) is a rare autosomal recessive disorder characterized by severe combined immunodeficiency (SCID) typically associated with the triad of erythrodermia, hepatosplenomegaly, and lymphadenopathy. 1 Other common symptoms include diarrhea, alopecia, and failure to thrive. 2 Occasionally, a similar clinical phenotype may be noticed in other immunodeficiency syndromes, [3] [4] [5] [6] and particularly in SCID with maternal T-cell engraftment.
Laboratory findings of OS include hypogammaglobulinemia with elevated serum IgE, defective antibody production, marked eosinophilia, and a variable number of autologous, activated, and oligoclonal T lymphocytes, that tend to infiltrate target organs and are generally poorly responsive to mitogens. [7] [8] [9] Villa et al 10 showed that OS is usually caused by hypomorphic mutations in the recombination activating gene (RAG)1 or RAG2 that result in residual protein expression and function. More recently, we found that patients with OS have defective thymic expression of Aire, a transcription factor that controls expression of tissue-specific peptides by thymic medullary epithelial cells. 11 This defect is likely to result in defective negative selection of autoreactive T cells in OS, that can therefore expand in the periphery in response to autoantigens.
In the absence of hematopoietic stem cell transplantation (HSCT), OS remains a fatal disorder due to increased susceptibility to infections with a high lethality early in life despite intensive supportive care. In contrast, transplantation of allogeneic hematopoetic stem cells can provide permanent cure. 12 In the past, satisfactory results have been obtained mostly with HSCT from HLA-matched family donors, whereas significant mortality and long-term morbidity have been reported in the literature for HSCT from mismatched family donors or from matched unrelated donors (MUD). 2, 12, 13 In particular, experience at a single center using related donors has resulted in 66.7% overall survival; 12 a lower success rate (16.7% survival) has been reported in another study focusing on mismatched related or matched unrelated bone marrow transplantation. 13 A recent review analyzed the outcome of 68 OS patients reported in the literature between 1965-1999. 2 The overall mortality of 41 evaluable patients was 59%; in particular, 69% of the untransplanted patients died within the first year of life, whereas mortality of the 28 transplanted OS patients was shown to be 46%.
We report here our single-center experience of allogeneic HSCT in 11 unselected patients with OS who were transplanted in the period between October 1991 and July 2002.
Patients and methods

Patients
We studied retrospectively 11 unselected patients with the clinical diagnosis of OS referred to the Department of Pediatrics, Children's University Hospital, Brescia, Italy, who received allogeneic HSCT between October 1991 and July 2002. Inclusion criteria were based on typical clinical and laboratory features of OS (Table 1) , associated with absence of maternal T-cell engraftment which may otherwise mimic OS and result in an 'Omenn-like' phenotype. The procedures for genetic analysis, HSCT, immunological follow-up, and data monitoring were approved by the local Ethical Committee, and informed consent was obtained from the patients' parents or their legal guardians.
Hematopoietic stem cell transplantation
HLA typing to ascertain recipient-donor compatibility was performed according to standard serologic methods in five patients and high-resolution molecular typing methods in six cases. The median age of recipients at the time of the first HSCT was 8.4 months (range: 4-18 months). Details of the HSCT procedures are reported in Table 2 . In all cases, the bone marrow was used as the source of hematopoietic stem cells; furthermore, in three cases donors agreed to donate also peripheral blood stem cells (PBSC). Mobilization of PBSC was induced by administration of granulocyte colony-stimulating factor (G-CSF) (10 mg/kg daily for 5 days); the PBSC were then harvested by leukapheresis.
Seven haploidentical transplants were performed in five infants, one of whom received three transplants. In one of these patients (OS1), HSCT was performed with bone marrow cells that had been T-cell depleted using Campath 1-M; for three patients (OS4, OS5, and OS6), positively selected CD34 þ BMSC and/or PBSC were obtained using the Isolex 300 system (Baxter). Patient OS8 received three attempts of haploidentical HSCT (one from her mother and two from her father), using positively selected CD34 þ BMSC and PBSC, purified with the Clinimacs System (Miltenyi), as described previously. 14 Three patients (OS2, OS3, and OS11) received a total of four attempts of HSCT from MUD; in all of these cases, unmanipulated bone marrow stem cells (BMSC) were used. Two patients (OS9, OS10) received three HSCT with unmanipulated BMSC from an HLA phenotypically identical parent. Finally, one patient (OS7) received unmanipulated BMSC from an HLA-identical sibling. A median of 6 Â 10 8 nucleated bone marrow cells per kilogram of body weight were infused (range: 3-11.3 Â 10 8 /kg). In the six transplants in which PBSC were also infused, the median dose of PBSC was 4.1 Â 10 6 CD34 þ cells/kg (range: 1-15 Â 10 6 /kg).
Conditioning regimen, supportive care, and graft-versus-host disease (GVHD) prophylaxis
As illustrated in Table 2 , myeloablative conditioning regimens were mainly based on busulfan and cyclophosphamide; the dose of the former was adjusted according to plasma levels after the first administration. Thio-Tepa (5-20 mg/kg) was used in six patients, most often in association with busulfan and cyclophosphamide. Seven patients received rabbit antithymocyte globulin (ATG, 10 mg/kg) daily for 3 days. A conditioning regimen based on fludarabine (200 mg/m 2 ) and melphalan (100 mg/m 2 ) was used in two patients. All patients had a central venous line and were nursed in protective isolation (laminar airflow) before and throughout the HSCT period. Appropriate antibiotic, antiviral, antifungal, and supportive prophy- /l, and red blood cell transfusions were used to keep hemoglobin levels 48.0 g/ dl. Prophylaxis of graft-versus-host (GvH) disease was used in all patients, and was based on cyclosporin A per os, adjusting the dose based on blood levels.
Survival was estimated by the Kaplan-Meier method, taking into consideration the event time for survival from date of transplantation to the date of death or date of last contact.
Engraftment and chimerism analysis
Regular blood cell counts were performed to survey engraftment. Myeloid engraftment was considered to have taken place on the first of three consecutive days during which the absolute neutrophil count (ANC) exceeded 0.5 Â 10 9 /l. Platelet recovery was defined to be achieved the day when the platelet count exceeded 20 Â 10 9 /l without transfusion within the preceding 3 days. Patients dying within 28 days after HSCT were considered not evaluable for engraftment. Graft failure was defined as the absence of engraftment within 30 days post HSCT.
Chimerism was assessed on positively selected CD3 þ T lymphocytes and CD19 þ B lymphocytes, as well as on granulocytes, by microsatellite analyses using probes for DQ alpha, D1S80 and ApoB. For chimerism analysis, positive selection of T and B lymphocytes was accomplished using monoclonal antibody-coated magnetic beads with the Minimacs System (Miltenyi).
Immunological reconstitution
Immunological reconstitution in the T-, B-, and natural killer (NK)-cell compartments was monitored by flow cytometry using a FACScalibur instrument, and monoclonal antibodies to CD3, CD4, CD8, CD19, and CD16. Naı¨ve and memory T cells were distinguished by their expression of CD45RA and CD45RO, respectively. The function and diversity of T lymphocytes were assessed by analyzing PHA-induced lymphocyte proliferation and the T-cell receptor repertoire, as described previously. 10 Thymic output was evaluated by measuring T-cell receptor excision circles (TRECs), as described. 15 
Mutation analysis
Prior to HSCT, blood samples were obtained upon informed consent from all patients and, when available, from their parents and their siblings. Following DNA extraction, PCR amplification and sequencing of the RAG1 and RAG2 gene coding sequences were performed as described.
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Results
Clinical and laboratory features at presentation
All patients included in this study had typical clinical features of OS ( Table 1 ). The median age at onset of symptoms was 30 days (range: 1-70 days). Generalized erythrodermia was present in all patients. Other common signs and symptoms included diarrhea and failure to thrive (90.9% of the patients), a history of recurrent infections (81.8%), lymphadenopathy (72.7%), and liver and/or spleen enlargement (54.5%). Interstitial pneumonia was present in three patients, and was due to CMV in two, and to respiratory syncytial virus in one. Patient OS9 had been vaccinated with Bacillus Calmette-Guerin (BCG) at birth, and showed signs of BCGosis.
All of the patients were of Italian origin, with the exception of patients OS9 and OS11 who were Slavians; parental consanguinity was not reported.
Laboratory features at presentation are shown in Table 3 . White blood cell count (WBC) ranged from 3.1 to 45.1 Â 10 9 /l, with a mean value of 16.6 Â 10 9 /l. With the exception of patient OS9, eosinophilia was present in all patients.
The absolute lymphocyte count was variable, as typically observed in OS. Six of the patients (OS2, OS3, OS5, OS8, OS9, OS11) were lymphopenic. Furthermore, significant abnormalities in the distribution of lymphocyte subsets were documented, including a skewed distribution of CD4 þ and CD8 þ T cells, an excess of activated/memory (CD45R0 þ ) vs naı¨ve (CD45RA þ ) T cells, and a low/ undetectable number of circulating B lymphocytes. In vitro proliferative response to PHA was abrogated in five patients, and reduced in other five patients. Only patient OS10 had a normal in vitro response to PHA. Three patients (OS1, OS5, and OS7) had a normal to increased proportion of circulating B lymphocytes, and two of them also had normal to increased serum IgM and IgA levels ( Table 3) . Low IgG serum levels were present in patient OS1, and had been documented at other referring centers in patients OS3 and OS8, who were receiving substitution therapy with intravenous immunoglobulins. Five additional patients had low IgA and/or IgM serum levels. Increased IgE serum levels were documented in three patients.
Mutation analysis at the RAG1 and RAG2 loci
Analysis of the coding sequence demonstrated mutations of the RAG1 gene in seven patients, and of the RAG2 gene in one patient (mutation data are available as Supplementary information). No mutations of the RAG genes were found in three patients (OS1, OS7, and OS8).
HSCT: engraftment, hematopoietic recovery, and GvHD
As shown in Table 2 , HSCT was performed at a mean age of 8.4 months (range: 4-18 months). The mean age at HSCT in the three patients undergoing MUD HSCT was In vitro proliferative response to PHA was considered low if lower than 30% of normal control, and absent if lower than 3% of normal control.
Stem cell transplantation in Omenn syndrome E Mazzolari et al 9.3 months. Three patients required multiple attempts of HSCT. In particular, patient OS8 showed rejection of maternal stem cells shortly after developing acute GvHD; she received a second transplant with paternal CD34 þ cells and because of slow engraftment received a third transplantation with paternal CD34 þ cells. Graft failure was documented in patient OS9 after the first attempt with maternal bone marrow cells; for this reason, this patient received a second HSCT. Finally, patient OS11 also received two attempts of HSCT because of slow engraftment, followed by rejection, after the first procedure. No toxicity related to the conditioning regimen was recorded in any of the patients. Taking into account only the successful procedures, the median time needed to achieve neutrophil recovery was 16.6 (range: 11-27) days. Withdrawal of red blood cell transfusions was possible after a median time of 17.1 (range: 8-31) days. Platelet engraftment was achieved at a median of 17.7 (range: 11-30) days.
Of the 11 patients, 10 showed evidence for engraftment of donor-derived cells. Patient OS1 died at day þ 63 due to graft failure and interstitial pneumonia. Of the 10 patients who were successfully engrafted, three patients (OS2, OS4, and OS10) showed no signs of acute GvHD (aGvHD), whereas seven patients developed aGvHD that was mostly confined to the skin. As shown in Table 2 , aGvHD greater than grade 2 was observed in two patients (OS8 and OS11), and was the cause of death in one of them (OS11), who had severe skin, gut, and liver involvement.
No cases of chronic GvHD were documented among the nine patients who survived beyond 100 days (Tables 2 and 3 ).
Immune reconstitution
Nine of the 11 patients survived more than 2 years after HSCT, and were therefore analyzed for the quality of immune reconstitution. The number of circulating CD3 þ lymphocytes increased rapidly after HSCT, and normalized in most patients within 1 year (Figure 1a) . The kinetics of T-cell reconstitution were slower in most of the infants who were treated by haploidentical HSCT, since they presented a low T-cell count at 3 months after HSCT. Distribution of CD4 þ and CD8 þ T lymphocytes, that was highly skewed at diagnosis, was also already normal at 3 months after HSCT (data not shown). Furthermore, with the exception of patient OS6, all long-term survivors were able to mount a vigorous T-lymphocyte proliferation in vitro in response to PHA already at 3 months of age (Figure 1b) . In all cases, the quality of T-cell reconstitution was sustained with time. Evaluation of thymic output, as measured by TRECs analysis at the last examination (mean interval from HSCT: 69.1 months; median: 72.5, range: 9-119 months), was normal or nearly normal in all nine long-term survivors (see: Supplementary data). These data were confirmed by the predominance of CD45RA þ cells within both CD4 þ and CD8 þ lymphocytes (data not shown). Moreover, analysis of T-cell diversity showed a fully polyclonal T-cell repertoire in four patients; four additional patients had a polyclonal repertoire with few dominant clones, and only one patient (OS3) displayed a restricted T-cell repertoire (data not shown).
While seven of the nine survivors had low or undetectable circulating B lymphocytes at diagnosis, all of them showed reconstitution of the B-lymphocyte compartment , and number of circulating CD19 þ lymphocytes (panel c) following HSCT for OS. In each of these panels, filled squares, filled triangles, empty triangles, and empty circles identify patients treated by HSCT from HLA-identical family donors, MUD, phenotypically-identical related donors, and haploidentical family donors, respectively. (Figure 1c) . Withdrawal of intravenous immunoglobulin substitution was possible in all patients, at a time interval from HSCT that ranged from 14 days to 4 years. Antibody response to vaccine antigens (tetanus toxoid and hepatitis B antigen) was tested after suspension of IVIG substitution therapy at least 1 year after HSCT, and was shown to be positive in all nine survivors. Seven patients also received conjugated pneumococcal vaccine, and all of them produced specific antibodies.
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Analysis of lymphoid chimerism in the nine survivors showed full donor chimerism in six and mixed chimerism in three patients (OS4, OS7, and OS10), with a proportion of donor-derived T cells ranging from 50% (in patient OS7) to 490% (in patients OS4 and OS10), and a proportion of donor B lymphocytes 480% in all three. This degree of mixed chimerism was stable over time.
Outcome of HSCT
Out of the 11 patients treated with HSCT, nine are alive at a median time of 94 months since HSCT (range: 30-146 months) (Figure 2 ). Seven of these nine patients are more than 6 years after HSCT.
Acute GvHD developed in seven out of 10 patients in whom engraftment of donor-derived lymphocytes was demonstrated. Patient OS1 died at day þ 63 due to graft failure and interstitial pneumonia without evidence of engraftment. Among the seven patients who developed aGvHD, this was mostly confined to the skin, and usually mild (Table 2) . However, severe aGvHD with gut and liver involvement was the cause of death in patient OS11. None of the nine patients who survived for at least 100 days after HSCT developed chronic GvHD.
Three patients developed autoimmune manifestations following HSCT, but all of them are currently well, without any evidence of autoimmunity, and do not require any treatment. In particular, patient OS4 at 5 months after HSCT developed idiopathic thrombocytopenic purpura that lasted for 13 months, and was followed by spontaneous remission. Patient OS11 developed autoimmune hepatitis at 8 months after HSCT, and hemolytic anemia 1 year after transplant; in both cases, steroids were effective. Finally, patient OS6 developed autoimmune manifestations (hemolytic anemia, hypothyroidism, and myasthenia gravis) at 7, 15, and 24 months after haploidentical HSCT. Interestingly, this patient belongs to a family with predisposition to autoimmunity, as the patient's mother has exophthalmos, moderately raised TSH levels, and positive antithyroid antibodies. Furthermore, her sister displays auto-immune thyroiditis and insulindependent diabetes mellitus, while a first cousin has insulindependent diabetes mellitus.
Of the nine survivors, seven are in excellent clinical conditions at home. Two patients have complications that are unrelated to HSCT. In particular, patient OS4 suffers from familial diplegia. Patient OS10 has reduced vision due to bilateral optical neuritis, an adverse effect of ethambutol that was required to treat disseminated BCG infection.
Discussion
Since the first reports on successful allogeneic bone marrow transplantation for otherwise lethal immunodeficiencies in 1968, 16, 17 , this procedure has been applied successfully for more than 30 years. While overall results of HSCT in SCID have shown significant improvement in recent years, less satisfactory data have been reported on long-term survival after HSCT in OS. A recent review analyzed the outcome of 68 OS patients reported in the literature between 1965 and 1999:
2 the overall mortality of the 28 transplanted OS patients was shown to be 46%. In particular, both pre-and post-transplant complications appear to be significantly more common and severe in patients with OS as compared to other forms of SCID, contributing significantly to posttransplant mortality. 13, 18 In this regard, recently nonmyeloablative stem cell transplantation has been proposed in order to reduce mortality. 19, 20 Furthermore, inadequate restoration of humoral immunity has been often reported, particularly after haploidentical HSCT.
At our center, during the last 13 years, we have been able to obtain sustained engraftment and long-term immune reconstitution in nine out of 11 consecutive infants treated by HSCT for OS. Importantly, donor-recipient HLA mismatch did not significantly affect the outcome. Several factors may account for the improved outcome of HSCT for OS in recent years.
Development of ex vivo procedures for isolation of CD34 þ stem cells has extended the potential benefit of HSCT from partially-matched related donors. Furthermore, co-infusion of donor PBSC (obtained after mobilization with granulocyte colony-stimulating factor, 10 mg/kg for 5 days) and bone marrow stem cells has been recently proposed, with the aim of increasing the cell dose and thus achieve faster engraftment after intensive conditioning regimen. 14 We have used this procedure in three of our transplants, but did not observe significant advantages.
Severe infections, hypovolemic shock, and multiple organ failure are important causes of death early in life in patients with OS. Immune dysregulation may also lead to significant clinical problems in OS, as in patient OS4 (who presented with nephritic-nephrotic syndrome and acute renal failure without infection), OS3 and OS5 (both of which showed signs of polyarthritis), and in patient OS8 Adequate supportive therapy and protective environment are essential to improve the clinical status of OS patients prior to HSCT. Isolation in laminar flow units since referral to our center, immunoglobulin substitution therapy, vigorous treatment with antibiotics, parenteral nutrition and albumin infusion (when needed), and topical or systemic immune suppression with steroids and/or cyclosporin A (to control immune dysreactivity) have been consistently used in all of our patients. This has allowed achievement of better and stable clinical conditions, and has often allowed search of MUD panels. The importance of aggressive therapeutic and supportive measures in infants with OS is also highlighted by the observation that during the same period (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) only one other infant with OS was referred to our center at 3 months of age in very severe clinical conditions, and died 2 weeks after admission with respiratory distress and myocarditis due to adenovirus.
Finally, age at HSCT is another important factor that may affect outcome. Myers et al. 21 have recently shown that early HSCT in the neonatal period leads to superior thymic output and thus improved survival in infants with SCID. While early recognition is essential to maximize the chances of successful outcome, we have been able to obtain prolonged survival and sustained immune reconstitution even in patients transplanted as late as at 18 months of life. This observation indicates that clinical status at the time of HSCT is more important than age among factors that may affect outcome of HSCT for OS.
Prior to this study, other reports of HSCT in series of patients with OS had not evaluated the possible role of the genetic defect. Although in most cases OS is due to mutations of either RAG1 or RAG2 genes, 7, 10, 22 it is now obvious that OS may also be sustained by other, most often unknown, genetic defects. Such genetic heterogeneity may contribute to some phenotypic variance among patients with OS. In our series, three patients had a normal number of circulating B lymphocytes, and two of them were not mutated in RAG genes. In addition, in contrast to what is generally reported in OS, a high proportion of our patients had normal or nearly normal IgM and IgA levels. Whether the genetic and phenotypic heterogeneity of OS may impact on the outcome of HSCT remains to be determined in larger series of patients.
Finally, successful correction of Rag2-deficient SCID has been reported in mice by gene transfer. 23 While this may open the way to similar experiences in humans, HSCT remains at present the standard way of treatment for OS. Our experience indicates that significant improvement has been obtained in the treatment of this life-threatening disease, even when no HLA-identical donors are available.
